Drug intelligence / Profile preview

PF-06818883

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

PF-06818883 is a small molecule drug developed by Pfizer as an inhibitor of monoacylglycerol lipase (MAGL, also known as MGLL). MAGL is an enzyme involved in the degradation of monoacylglycerols, including the endocannabinoid 2-arachidonoylglycerol (2-AG), which plays a role in neuroinflammation and other central nervous system processes. The primary indication investigated for this compound was intracerebral hemorrhage. Clinical development reached Phase 1 but was discontinued before further advancement[1][2][7].

Targets

MGLL (Monoacylglycerol lipase)

Beyond the preview

Go deeper on PF-06818883.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06818883.

Explore the full profile